foxo4-dri senolytic peptide animal model 2023 2024

foxo4-dri senolytic peptide animal model 2023 2024 Senolytics: from pharmacological inhibitors to immunotherapies, a promising future for patients' treatment Molecular modelling of the FOXO4-TP53

Name: foxo4-dri senolytic peptide animal model 2023 2024 Senolytics: from pharmacological inhibitors to immunotherapies, a promising future for patients' treatment Molecular modelling of the FOXO4-TP53
Brand: cantondelareina.com.ar
SKU: 65662539103
Price: 25.79 USD
Availability: InStock
Rating: 4.6237 (9 reviews)

Molecular modelling of the FOXO4 TP53 interaction to design senolytic peptides for the elimination of senescent cancer cells ScienceDirect Targeting the FOXO4 p53 axis by retro inverso peptide senolytic agents: a pharmacological strategy to mitigate brain aging and cognitive decline Naunyn Schmiedeberg's Archives of Pharmacology Springer Nature Link The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4 DRI Nature Communications FOXO4 DRI part 1 , #peptide #molecule #research #health #information

SKU: 65662539103 · From cantondelareina.com.ar

4.6

USD25.79 USD72.79

Pay in 4 interest-free payments of $6.45 Learn more

Shipping Estimate
USA

USA

CAN

Ships within 48 hours · Estimated delivery Aug 12 - Aug 17

Description

MHRA guidance requires that products are labelled 'for research purposes only' and make no medical claims regarding disease treatment or prevention.

GHK Cu is a synthetic coppertripeptide complex composed of glycyl L histidyl L lysine (GHK) chelated with copper(II), used in research to study tissue remodeling, extracellular matrix regulation, and copper dependent signaling in vitro and in animal models

- A detailed community debate on whether GHK-Cu functions as a 5-alpha reductase inhibitor, with personal lab results from members using both topical and injectable forms